Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)

被引：289

作者：

Anderson, DR

Hegde, S

Reinhard, E

Gomez, L

Vernier, WF

Lee, L

Liu, S

Sambandam, A

Snider, PA

Masih, L

机构：

[1] Pfizer Global Res & Dev, Chesterfield, MO 63017 USA

[2] Albany Mol Res Inc, Albany, NY 12212 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 06期

关键词：

MK-2; kinase inhibitor; TNF alpha;

D O I：

10.1016/j.bmcl.2005.01.067

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A class of inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) was discovered. These compounds have demonstrated activity against the enzyme with IC50 values as low as 130 nM and suppress the expression of TNFα in U937 cells. These represent the first small molecule inhibitors of MK-2 to be reported. © 2005 Elsevier Ltd. All rights reserved.

引用

页码：1587 / 1590

页数：4

共 7 条

[1] The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis
Camussi, G
Lupia, E
[J]. DRUGS, 1998, 55 (05) : 613 - 620
[2] MAP kinases
Chen, Z
Gibson, TB
Robinson, F
Silvestro, L
Pearson, G
Xu, BE
Wright, A
Vanderbilt, C
Cobb, MH
[J]. CHEMICAL REVIEWS, 2001, 101 (08) : 2449 - 2476
[3] Haddad J J, 2001, Curr Opin Investig Drugs, V2, P1070
[4] MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis
Kotlyarov, A
Neininger, A
Schubert, C
Eckert, R
Birchmeier, C
Volk, HD
Gaestel, M
[J]. NATURE CELL BIOLOGY, 1999, 1 (02) : 94 - 97
[5] MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels
Neininger, A
Kontoyiannis, D
Kotlyarov, A
Winzen, R
Eckert, R
Volk, HD
Holtmann, H
Kollias, G
Gaestel, M
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (05) : 3065 - 3068
[6] Pargellis Christopher, 2003, Curr Opin Investig Drugs, V4, P566
[7] Tumour necrosis factor-α blockers in rheumatoid arthritis -: Review of the clinical experience
Richard-Miceli, C
Dougados, M
[J]. BIODRUGS, 2001, 15 (04) : 251 - 259

← 1 →